Companies › Eli Radiopharma
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [18F]Flortaucipir Injection Tau neurofibrillary tangle (NFT) PET imaging agent - binds to aggregated tau protein | MAPT | Phase 1 | AD - Alzheimer's Disease | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07580703 | [18F]Flortaucipir Injection | Phase 1 | AD - Alzheimer's Disease | Neurology | Dec 2026 |
Bristol-Myers Squibb Roche Voyager Therapeutics Amyloid Solution Arrowhead Pharmaceuticals Nuravax Oligomerix UCB Biopharma SRL
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.